New call-to-action
New call-to-action
New call-to-action

Foundation for Prader-Willi Blog | News (6)

Categories

Recordings from FPWR’s Annual Family Conference: What’s Next for DCCR?

Soleno Therapeutics recently shared data from their DESTINY PWS study, an international, placebo-controlled Phase 3 study of DCCR (Diazoxide Choline Controlled-Release) drug trial. To further establish the effects of DCCR administration on hyperphagi...
October 25, 2023 Read More

Topics: News, Hunger Satiety, Research

2023 Harvesting Hope Distance Challenge: Make a Real Difference

The Harvesting Hope Distance Challenge is back, and it's your chance to join a heartwarming community, get moving, and make a real difference. Whether you're a seasoned walker, a jogging enthusiast, or someone who just loves the idea of taking positi...
October 3, 2023 Read More

Topics: News

FPWR Partners with PWSA | USA to Provide BOSS Social Skills Groups for Teens and Adults with PWS

PWSA | USA (Prader-Willi Syndrome Association | USA) and FPWR (Foundation for Prader-Willi Research) are thrilled to announce a groundbreaking collaboration to address the social challenges faced by individuals with Prader-Willi syndrome (PWS). FPWR ...
September 27, 2023 Read More

Topics: News

Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

We are excited to share the news that Soleno has announced positive, statistically significant top-line results from the randomized withdrawal period of study c602 of DCCR for Prader-Willi Syndrome. In the study, patients taking DCCR showed a highly ...
September 26, 2023 Read More

Topics: News, Clinical Trials

Life-Changing Connections: Families Share Why They Love the FPWR Conference

Attending a conference means being around people who get it—they understand the journey you have been on with your child, personally, and with the world. It’s like seeing your family when you attend the FPWR Family Conference. Everyone, whether a new...
August 22, 2023 Read More

Topics: News

Aardvark Announces Rare Disease Designation and Expands Ongoing Phase 2 Trial

Aardvark Therapeutics, a clinical stage biopharmaceutical company, has reported receipt of a Rare Pediatric Disease Designation in Prader-Willi Syndrome (PWS) from the FDA for its lead program ARD-101.
August 3, 2023 Read More

Topics: News, Clinical Trials

Innovative FPWR-Funded Projects Receive Additional Funding

FPWR’s grant program focuses on supporting innovative, high risk/high reward research in its early stages, with particular emphasis on supporting projects that will lead to new treatments for PWS.
May 23, 2023 Read More

Topics: News

New Venture Philanthropy Investment: Palobiofarma

The Foundation for Prader-Willi Research (FPWR) has provided a new venture philanthropy award, in the form of a convertible loan, to Palobiofarma S.L., a Spanish biopharmaceutical company focused on developing innovative treatments for serious diseas...
May 4, 2023 Read More

Topics: News

FPWR 2023 Conference Standards of Care

You won’t want to miss these speakers at the 2023 FPWR Family Conference this October in Denver, CO.
April 7, 2023 Read More

Topics: News, Family Conference

About FPWR

The Foundation for Prader-Willi Research (federal tax id 31-1763110) is a nonprofit corporation with federal tax exempt status as a public charity under section 501(c)(3).

4star120x60

NORD_MembershipLogo_Platinum_2021

excellence-in-giving-logo

Main Menu

Our Mission

The mission of FPWR is to eliminate the challenges of Prader-Willi syndrome through the advancement of research and therapeutic development.

Contact Us

Foundation for Prader-Willi Research
Phone: 888-322-5487
Email: info@fpwr.org

FPWR
440 N Barranca Ave #3620
Covina, CA 91723

Copyright © 2020. All Rights Reserved. Terms of Use. Privacy Policy. Copyright Infringement Policy. Disclosure Statement.